BCAX Valuation

Bicara Therapeutics Inc

Add to Watchlist

Advanced Chart

11.640

+0.23(2.016%)1D

Overview
Forecast
Valuation
Earnings

BCAX Relative Valuation

BCAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BCAX is overvalued; if below, it's undervalued.

Historical Valuation

Bicara Therapeutics Inc (BCAX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -8.38. The fair price of Bicara Therapeutics Inc (BCAX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：11.64

Fair

-4.99

Trailing

Forward

-1.14

EV/EBITDA

Bicara Therapeutics Inc. (BCAX) has a current EV/EBITDA of -1.14. The 5-year average EV/EBITDA is -3.44. The thresholds are as follows: Strongly Undervalued below -12.04, Undervalued between -12.04 and -7.74, Fairly Valued between 0.86 and -7.74, Overvalued between 0.86 and 5.16, and Strongly Overvalued above 5.16. The current Forward EV/EBITDA of -1.14 falls within the Historic Trend Line -Fairly Valued range.

-1.17

EV/EBIT

Bicara Therapeutics Inc. (BCAX) has a current EV/EBIT of -1.17. The 5-year average EV/EBIT is -3.37. The thresholds are as follows: Strongly Undervalued below -11.53, Undervalued between -11.53 and -7.45, Fairly Valued between 0.72 and -7.45, Overvalued between 0.72 and 4.80, and Strongly Overvalued above 4.80. The current Forward EV/EBIT of -1.17 falls within the Historic Trend Line -Fairly Valued range.

0.00

Bicara Therapeutics Inc. (BCAX) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-6.52

P/OCF

Bicara Therapeutics Inc. (BCAX) has a current P/OCF of -6.52. The 5-year average P/OCF is -9.57. The thresholds are as follows: Strongly Undervalued below -17.94, Undervalued between -17.94 and -13.76, Fairly Valued between -5.39 and -13.76, Overvalued between -5.39 and -1.21, and Strongly Overvalued above -1.21. The current Forward P/OCF of -6.52 falls within the Historic Trend Line -Fairly Valued range.

-4.12

P/FCF

Bicara Therapeutics Inc. (BCAX) has a current P/FCF of -4.12. The 5-year average P/FCF is -7.18. The thresholds are as follows: Strongly Undervalued below -15.30, Undervalued between -15.30 and -11.24, Fairly Valued between -3.12 and -11.24, Overvalued between -3.12 and 0.94, and Strongly Overvalued above 0.94. The current Forward P/FCF of -4.12 falls within the Historic Trend Line -Fairly Valued range.

Bicara Therapeutics Inc (BCAX) has a current Price-to-Book (P/B) ratio of 1.46. Compared to its 3-year average P/B ratio of 1.07 , the current P/B ratio is approximately 36.18% higher. Relative to its 5-year average P/B ratio of 1.07, the current P/B ratio is about 36.18% higher. Bicara Therapeutics Inc (BCAX) has a Forward Free Cash Flow (FCF) yield of approximately -16.22%. Compared to its 3-year average FCF yield of -9.40%, the current FCF yield is approximately 72.61% lower. Relative to its 5-year average FCF yield of -9.40% , the current FCF yield is about 72.61% lower.

1.46

P/B

Median3y

1.07

Median5y

1.07

-16.22

FCF Yield

Median3y

-9.40

Median5y

-9.40

Competitors Valuation Multiple

The average P/S ratio for BCAX's competitors is 53.36, providing a benchmark for relative valuation. Bicara Therapeutics Inc Corp (BCAX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BCAX.O

Bicara Therapeutics Inc

Kalvista Pharmaceuticals Inc

18.64

643.40M

ABUS.O

Arbutus Biopharma Corp

SIGA Technologies Inc

Theravance Biopharma Inc

Maze Therapeutics Inc

Loss

0.00

Performance Decomposition

Market capitalization of BCAX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of BCAX in the past 1 year is driven by Unknown.